Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/Docetaxel + Pembrolizumab in BCG-Unresponsive NMIBC
NCT06972615Phase 2Recruiting
- Sponsor
- Blatam
- Start
- May 2026
- Primary completion
- Dec 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Blatam. Started May 2026; status: recruiting.
02
Drugs
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06972615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972615.